Benefits
Cbio has perfected the TIL manufacturing process with its proprietary technology providing novoleucel with a number of differentiated benefits versus standard IL-2 only expanded TILs:
LESS STARTING MATERIAL
1-2 cm3
→
1-3 MM3
Allows for fine needle biopsy – 2-3 times more patients can be treated as no surgery is required
REDUCED PRODUCTION TIME
49 Days
→
20 Days
Time matters – the health of late-stage cancer patients can quickly deteriorate
HIGHER POTENCY
3X TUMOR REACTIVE
More tumor reactive T-cells in TIL product – potential improved clinical outcome
IMPROVED SUCCESS RATE
68%
→
98%
50% more patients can be offered novoleucel TIL therapy – also in less immunogenic cancers
SCALABLE, LESS MANUAL STEPS
2,437
→
378
Manufacturability and scalability are critical parameters for a commercially viable TIL product
CRYOPRESERVED FINAL PRODUCT
20°C
→
-180°C PRODUCT
With a cryopreserved final product formulation, novoleucel can be distributed globally